Hammond Janet MJ 4

4 · Atea Pharmaceuticals, Inc. · Filed Feb 3, 2026

AI-generated summary of this filing

Updated Feb 4, 2026

Atea (AVIR) CDO Janet Hammond Receives RSUs and Exercises Options

What Happened

Janet Hammond, Chief Development Officer at Atea Pharmaceuticals (AVIR), had a large grant/vesting event and conversions of derivatives on January 31, 2026. The filing shows a 177,000-share award/RSU acquisition and multiple derivative exercise/conversion entries. To cover tax withholding, 14,136 shares were surrendered/sold at $4.24 per share for $59,937.
The report also lists exercise/conversion activity (separate derivative entries of 58,050 shares acquired and 46,800 and 11,250 shares marked as disposed at $0.00), indicating conversion/settlement of previously granted derivative awards or RSUs/PSUs that vested on that date.

Key Details

Transaction date: January 31, 2026; Form 4 filed February 3, 2026.
Tax withholding: 14,136 shares disposed at $4.24 = $59,937 (marked as code F).
Awards/vesting: 177,000 shares reported as a grant/award or RSU conversion (code A / M) at $0.00 (derivative settlement).
Other derivative entries: 58,050 shares acquired (M), and disposals of 46,800 and 11,250 shares (M) reported at $0.00.
Footnotes: F1 = each RSU equals one share; F3/F4 = original RSUs and performance RSUs vested as of Jan 31, 2026; F2 = includes 2,363 shares from the 2020 ESPP; F5 notes an option grants vesting monthly after Jan 31, 2026.
Shares owned after the reported transactions: not specified in the provided excerpt of the filing.
Filing timeliness: Form filed Feb 3, 2026 reporting Jan 31 transactions; the filing shows no late-filing flag in the provided data.

Context

This appears to be a routine vesting/settlement of restricted stock units and performance awards, not an open-market purchase or discretionary sale. The sale of 14,136 shares was to satisfy tax withholding on the vesting/settlement (common with RSU/PSU vesting).
Derivative entries at $0.00 typically reflect conversion/settlement of RSUs or performance awards rather than a cash purchase; F1–F4 clarify these are RSU/performance-RSU related events.
For retail investors: the event is primarily an insider receiving vested/awarded shares (a non-cash, compensation-related acquisition) with a small, routine share disposition to cover taxes — not necessarily a signal of buying or selling intent in the open market.

Form 4

Period: 2026-01-31

Chief Development Officer

Transactions

Exercise/Conversion
Common Stock
[F1][F2]
2026-01-31+58,050→ 141,801 total
Tax Payment
Common Stock
2026-01-31$4.24/sh−14,136$59,937→ 127,665 total
Exercise/Conversion
Restricted Stock Units
[F1][F3]
2026-01-31−46,800→ 0 total
→ Common Stock (46,800 underlying)
Exercise/Conversion
Restricted Stock Units
[F1][F4]
2026-01-31−11,250→ 0 total
→ Common Stock (11,250 underlying)
Award
Stock Option (Right to Buy)
[F5]
2026-01-31+177,000→ 177,000 total
Exercise: $4.24Exp: 2036-01-30→ Common Stock (177,000 underlying)

Footnotes (5)

[F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
[F2]Includes 2,363 additional shares acquired under the Atea Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan.
[F3]The original grant of 140,400 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026.
[F4]Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026.
[F5]The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2026 such that the option is fully vested on January 31, 2030.

Signature

/s/ Andrea Corcoran, as Attorney-in-Fact for Janet Hammond|2026-02-03

1 file